Biodesix Inc. Common Stock (BDSX)
Stock · NASDAQ · Health Care
$23.66as of 10/16/2026
Price chart
BDSX Signal Track Record
How signals performed across all stocks →What BDSX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 23 | +0.6% | 57% | September 21, 2026 |
| Bollinger Band Breakout | 22 | -0.2% | 50% | August 21, 2026 |
| Bollinger Band Breakdown | 20 | -0.1% | 50% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -11.6% | 29% | December 31, 2024 |
| Any 20-session window (baseline) | -1.3% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 334
- Website
- www.biodesix.com/
Fundamentals
- 1-day range
- $23.13$24.79
- Market cap
- $228.86M
- P/E (trailing)
- —
- P/E (forward)
- -106.16
- EPS (trailing)
- $-3.17
- Dividend yield
- —
- Beta
- 0.61
- Avg. volume
- 99.8K
How Biodesix Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Biodesix Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BDSXBiodesix Inc. Common Stock$23.66▼ 4.25%Market cap $228.86MP/E —$5.26$31.97
- ACHAccendra Health Inc. Common Stock$0.24▼ 7.69%Market cap $223.62MP/E —$0.2615$5.6
- YDESYD Bio Limited Ordinary Shares$5.92▼ 12.17%Market cap $167.45MP/E —$1.7$22
- XGNExagen Inc. Common Stock$7.72▼ 9.81%Market cap $159.64MP/E —$2.59$12.23
- TLSITriSalus Life Sciences Inc. Common Stock$3.63▼ 6.92%Market cap $299.10MP/E —$2.2$7.95
- KEQUKewaunee Scientific Corporation Common Stock$32.93▲ 2.30%Market cap $108.73MP/E 11.26$32$46.57
- TLSIWTriSalus Life Sciences Inc. Warrant$0.8799▼ 2.23%Market cap $101.95MP/E —$0.4405$1.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BDSX Biodesix Inc. Common Stock | $228.86M | — | $23.66 | ▼ 4.25% | $5.26$31.97 |
| ACH Accendra Health Inc. Common Stock | $223.62M | — | $0.24 | ▼ 7.69% | $0.2615$5.6 |
| YDES YD Bio Limited Ordinary Shares | $167.45M | — | $5.92 | ▼ 12.17% | $1.7$22 |
| XGN Exagen Inc. Common Stock | $159.64M | — | $7.72 | ▼ 9.81% | $2.59$12.23 |
| TLSI TriSalus Life Sciences Inc. Common Stock | $299.10M | — | $3.63 | ▼ 6.92% | $2.2$7.95 |
| KEQU Kewaunee Scientific Corporation Common Stock | $108.73M | 11.26 | $32.93 | ▲ 2.30% | $32$46.57 |
| TLSIW TriSalus Life Sciences Inc. Warrant | $101.95M | — | $0.8799 | ▼ 2.23% | $0.4405$1.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- PATIENCE JOHN · June 30, 2026 · Option Exercise1.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.56M
- Total value held
- $50.82M
- Institutional holders
- 37
- Unknown758.3K
- Unknown489.8K
- Unknown458.4K
- Unknown416.6K
- Unknown255.2K
- Unknown238.0K
- Unknown141.6K
- Unknown132.1K
- Unknown70.0K
- Unknown69.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships
Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.